KLK3 and prostate carcinoma: Other survival outcomes analysed in the identified studies included failure-free survival, time to progression, disease-free survival, time to prostate-specific antigen progression, recurrence-free survival, distant metastasis-free survival, time-to-castration-resistant prostate cancer, time to failure and disease-specific survival (Fig 2).